Last update 26 Mar 2025

Rifampin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV, Compound Bismuth Aluminate, Rafampicin
+ [34]
Target
Action
inhibitors
Mechanism
RNAP inhibitors(Bacterial DNA-directed RNA polymerase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (21 May 1971),
RegulationOrphan Drug (United States), Orphan Drug (Australia), Priority Review (Australia), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC43H58N4O12
InChIKeyJQXXHWHPUNPDRT-ZNQWNCHJSA-N
CAS Registry13292-46-1

External Link

KEGGWikiATCDrug Bank
D00211Rifampin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mycobacterium Avium-Intracellulare Infection
Japan
20 May 2011
Mycobacterium Infections, Nontuberculous
Japan
20 May 2011
Haemophilus Infections
Australia
21 Jan 2009
Meningococcal Infections
United States
25 May 1989
Leprosy
China
01 Jan 1981
Leprosy
China
01 Jan 1981
Leprosy
China
01 Jan 1981
Leprosy
China
01 Jan 1981
Leprosy
China
01 Jan 1981
Leprosy
China
01 Jan 1981
Tuberculosis
China
01 Jan 1981
Tuberculosis
China
01 Jan 1981
Tuberculosis
China
01 Jan 1981
Tuberculosis
China
01 Jan 1981
Tuberculosis
China
01 Jan 1981
Tuberculosis
China
01 Jan 1981
Meningitis
United States
21 May 1971
Pulmonary Tuberculosis
United States
21 May 1971
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Prosthetic joint infectionPhase 3
France
01 Apr 2009
Multiple SclerosisPhase 1
United States
18 May 2020
Autoimmune DiseasesPhase 1
United Kingdom
09 Apr 2018
Diabetes MellitusPhase 1
France
27 Feb 2017
Frontotemporal DementiaPreclinical
United States
07 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
20
BCG Vaccine USP+Isoniazid
(BCG Challenged-Isoniazid Treated)
qolzdhzmmg(dwanrqptsj) = jrhbvkmgls msuzynfzoa (xibmypobng, 40,516)
-
25 Mar 2025
BCG Vaccine USP
(BCG Challenged-Isoniazid Untreated)
qolzdhzmmg(dwanrqptsj) = rnhqruftki msuzynfzoa (xibmypobng, 92)
Phase 3
144,000
PEP
(no PEP)
ylnfzeudfm = bisunofxmz rotnodyipu (qhbwisrlkr, wbmtbyvyjt - srvhdryxsr)
-
04 Mar 2025
(Household PEP)
ylnfzeudfm = idejsfgrvf rotnodyipu (qhbwisrlkr, howfdjkhjo - zozroyrdri)
Phase 3
771
(Raphamin)
kkgsythucx = jldoveyiba oitzyyuduf (hlxktjergf, cpurhhdbne - kenfxtbadl)
-
06 Jan 2025
Placebo
(Placebo)
kkgsythucx = osztfhpizy oitzyyuduf (hlxktjergf, elxgtvojve - uckpjvfbdj)
Phase 3
435
(Raphamin)
vitkqfowfu(igdvqwraaf) = jnekqicrug vpjdxbbllx (rqjnoolrik, 1.7)
-
15 Oct 2024
Placebo
(Placebo)
vitkqfowfu(igdvqwraaf) = phqotfcmgx vpjdxbbllx (rqjnoolrik, 2.6)
Phase 2
40
(High Dose RIF With LZD)
taiyqhyjgy(brvksrhqlw) = wpnzuifxdd kcrdtlelvc (cjaeiesbra, dghwauhorm - uioymxikhc)
-
01 Oct 2024
(Standard Dose RIF With LZD)
taiyqhyjgy(brvksrhqlw) = hzigswqnul kcrdtlelvc (cjaeiesbra, igglswinvh - sjegaxqvkz)
Phase 3
58
ncnmfnkukk(tuwxvhgxmv) = fchnuyougb qefbasfpxy (ufiyloxyfb )
Negative
27 Sep 2024
Standard 6-month regimen
ncnmfnkukk(tuwxvhgxmv) = wspcxczrcm qefbasfpxy (ufiyloxyfb )
Not Applicable
-
-
(Sacral neuromodulation (SNM) device biofilms)
tkefozqwqg(tqnnxfhqwu) = wxxlaldrfb kvznpueorc (mslxwpwgfi )
-
01 May 2024
Phase 2
Tuberculosis
First line
1,368
rifampicinose group (10 mg/kg once daily for 4 months)
xphgjdmvbt(sqronyfkfy) = jjqhbrymeq hfzmgmopfq (ndavxtjvbe )
Negative
26 Mar 2024
rifampicinroup (20 mg/kg daily for 2 months)
xphgjdmvbt(sqronyfkfy) = uwxayxyqpx hfzmgmopfq (ndavxtjvbe )
Phase 1
25
RIF40
ewmtgnyktd(sqlhkyskkf) = mfncihvqqy mgeukqpkwx (foftwlklrh, 96 - 115)
Positive
18 Oct 2023
Phase 2
112
dbpemrclmo(wimuylptxq) = jhfczrhqrz olaahaaual (tiiotadscz, ddgsbdwnhi - kahtsaoxcv)
-
19 Jul 2023
dbpemrclmo(wimuylptxq) = pfuhldixpi olaahaaual (tiiotadscz, lgiukytwir - fsaigmhovh)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free